INCIDENCE OF ADENOVIRUS INFECTIONS IN PEDIATRIC AND ADULT ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS IN EUROPE
|
|
- Jordan Hubbard
- 6 years ago
- Views:
Transcription
1 INCIDENCE OF ADENOVIRUS INFECTIONS IN PEDIATRIC AND ADULT ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS IN EUROPE Sebastian Voigt, 1 Cécile Pochon, 2 Kanchan Rao, 3 Antonio Pérez-Martínez, 4 Marco Zecca, 5 Enrikas Vainorius, 6 Tom Brundage, 6 Artak Khachatryan, 7 Essy Mozaffari, 6 Garrett Nichols 6 1 Charité-Universitätsmedizin Berlin, Department of Pediatric Oncology/Hematology/Stem Cell Transplantation, Berlin, Germany; 2 University Hospital of Nancy, Allogeneic Hematopoietic Stem Cell Transplantation Unit, Department of Hematology, Vandoeuvre-lès-Nancy, France; 3 Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom; 4 Hospital Universidad Autónoma de Madrid, Madrid, Spain; 5 Fondazione IRCCS Policlinico San Matteo, Pediatric Hematology/Oncology, Pavia, Italy; 6 Chimerix, Durham, NC, United States; 7 Analytica-Laser, London, United Kingdom 1
2 Disclosures SV, CP, KR, APM, and MZ are investigators in the AdVance study sponsored by Chimerix EV, TB, EM, and GN are employees of the study sponsor, Chimerix AK is an employee of Analytica-Laser, a research consultancy who conducted the study on behalf of the sponsor, Chimerix 2
3 Allo-HCT recipients are at increased risk of viral infection Viral infections may lead to life-threatening conditions that further complicate the management of allogeneic-hematopoietic cell transplant (allo-hct) recipients 1,2 Pediatric allo-hct patients are at particularly high risk for development of adenovirus (AdV) infections 2 Current evidence regarding AdV epidemiology after allo-hct is generally limited to single-center studies 2,3 1 Lin R and Liu Q, J Hematol Oncol. 2013;6:94. 2 Lion T. Clin Microbiol Rev. 2014;27: Ison M. Clin Infect Dis. 2006;43:
4 The AdVance study AdVance is a retrospective, multicenter, multinational study of the incidence, management, and clinical outcomes of AdV infection in allo-hct recipients Data were from transplants between January 2013 and September 2015 at participating centers Quantitative and qualitative data were extracted for AdV infection, AdV viremia, and AdV viremia 1000 copies/ml within 6 months of transplant o Results were stratified by age (pediatric [<18 years] vs adult) 50 centers in total 4
5 Objectives As part of the AdVance study, the incidence of AdV infection was evaluated in pediatric and adult allo-hct recipients Other presentations of AdVance data at EBMT 2018: The next presentation will share data on the outcomes of AdV infection Two posters are also presenting AdVance results today: o B043 shares results of a practice patterns survey o B073 presents the impact of AdV infection on hospitalization duration among pediatric allo-hct recipients 5
6 Baseline characteristics for pediatric patients Sex Male 1099 (63%) Age Median years 7 Underlying condition Graft type Malignant 1111 (64%) Non-malignant immunodeficient Non-malignant immunocompetent 427 (25%) 200 (11%) Bone marrow 934 (54%) Peripheral blood stem cell 549 (31%) Cord blood 255 (15%) Donor type 1 Conditioning T-cell depletion Matched-related 490 (28%) Matched-unrelated 701 (40%) Mismatched 179 (10%) Haploidentical 270 (15%) Myeloablative 1481 (85%) Non-myeloablative 257 (15%) Ex-vivo 283 (16%) Serotherapy (ATG) 753 (43%) Serotherapy (Campath) 252 (15%) None 450 (26%) Patients were from centers in Italy (431 patients), UK (388), Spain (324), France (214), Germany (214), Netherlands (91), and Czech Republic (76) n recipients (%), unless otherwise stated. 1 Non-exclusive categories Allo-HCT recipients n=1738 6
7 Baseline characteristics for adult patients Sex Male 1462 (58%) Age Median years 51 Underlying condition Graft type Malignant 2477 (97%) Non-malignant immunodeficient Non-malignant immunocompetent n recipients (%), unless otherwise stated. 1 Non-exclusive categories 19 (1%) 42 (2%) Bone marrow 466 (18%) Peripheral blood stem cell 1880 (74%) Cord blood 192 (8%) Allo-HCT recipients n=2538 Donor type 1 Conditioning T-cell depletion Matched-related 902 (35%) Matched-unrelated 976 (38%) Mismatched 326 (13%) Haploidentical 290 (11%) Myeloablative 1710 (67%) Non-myeloablative 828 (33%) Ex-vivo 737 (29%) Serotherapy (ATG) 728 (29%) Serotherapy (Campath) 228 (9%) None 845 (33%) Patients were from centers in France (924 patients), Spain (743), Italy (359), UK (270), Germany (239), Netherlands (2), and Czech Republic (1) 7
8 1 in 3 pediatric HCT recipients had an AdV infection Pediatric allo-hct recipients n=1738 Any AdV infection 1 n=558 (32%) AdV viremia 1 n=395 (23%) 93% (519/558) of AdV infections were identified as part of routine screening practices See poster B043 for more details on practice patterns AdV viremia 1000 copies/ml n=241 (14%) Less than half of patients with AdV infection had viremia 1000 copies/ml 1 Within 6 months of transplant 8
9 2 in 5 had a concurrent dsdna viral infection 1000 Of 241 pediatric allo-hct recipients with AdV viremia 1000 copies/ml: 66% had 1 concurrent infection (bacterial/fungal/viral) 1 27% had CMV coinfection 1 dsdna viral coinfection 1 n=241 CMV 65 (27%) EBV 42 (17%) BKV 22 (9%) CMV, EBV, and/or BKV 103 (43%) n recipients (%). CMV, Cytomegalovirus; EBV, Epstein Barr virus; BKV, BK virus. 1 At the time of first AdV infection identification. Non-exclusive categories 9
10 6% of adult HCT recipients had an AdV infection Adult allo-hct recipients n=2538 Any AdV infection 1 n=141 (6%) AdV viremia 1 n=77 (3%) 72% (101/141) of AdV infections were identified as part of routine screening practices See poster B043 for more details on practice patterns AdV viremia 1000 copies/ml n=39 (2%) 1 Within 6 months of transplant 10
11 2 in 3 had a concurrent dsdna infection 1000 Of 39 adult allo-hct recipients with AdV viremia 1000 copies/ml: 79% had 1 concurrent infection (bacterial/fungal/viral) 1 Half (51%) had CMV coinfection 1 dsdna viral coinfection 1 n=39 CMV 20 (51%) EBV 9 (23%) BKV 9 (23%) CMV, EBV, and/or BKV 26 (67%) n recipients (%). CMV, Cytomegalovirus; EBV, Epstein Barr virus; BKV, BK virus. 1 At the time of first AdV infection identification. Non-exclusive categories 11
12 AdV viremia 1000 copies/ml develops more quickly in pediatric patients 1000 Pediatric Adult Median time to first AdV viremia 1000 copies/ml: 26 days (IQR: 13, 56) Median time to first AdV viremia 1000 copies/ml: 61 days (IQR: 33, 91) IQR, interquartile range (1 st, 4 th ) 12
13 Incidence of AdV viremia 1000 copies/ml in pediatrics by transplant characteristics The highest incidence was observed in patients with Campath serotherapy or a mismatched donor Underlying condition Graft type Pediatric allo-hct recipients with AdV viremia ( 1000 copies/ml); n=241 Malignant 148/1111 (13%) Non-malignant immunodeficient Non-malignant immunocompetent 72/427 (17%) 21/200 (10%) Bone marrow 116/934 (12%) Peripheral blood stem cell 92/549 (17%) Cord blood 33/255 (13%) Pediatric allo-hct recipients with AdV viremia ( 1000 copies/ml); n=241 Allo-HCT recipients with AdV viremia 1000 copies/ml n=241 n recipients with AdV viremia 1000 copies/ml/n with baseline characteristic (%) 1 Non-exclusive categories Donor type 1 Conditioning T-cell depletion Matched-related 33/490 (7%) Matched-unrelated 100/701 (14%) Mismatched 43/179 (24%) Haploidentical 49/270 (18%) Myeloablative 202/1481 (14%) Non-myeloablative 39/257 (15%) Ex-vivo 53/283 (19%) Serotherapy (ATG) 95/753 (13%) Serotherapy (Campath) 62/252 (25%) None 31/450 (7%)
14 Age Age, donor type, and use of T-cell depletion were prognostic factors for AdV viremia 1000 copies/ml Pediatric allo-hct recipients 1000 Gender Conditioning Disease Donor type T-cell Depletion 14
15 Incidence of AdV viremia 1000 copies/ml in adults by transplant characteristics The highest incidence was observed in those with Campath serotherapy 1000 Underlying condition Graft type Adult allo-hct recipients with AdV viremia ( 1000 copies/ml); n=39 Malignant 38/2477 (2%) Non-malignant immunodeficient Non-malignant immunocompetent 1/19 (5%) 0/42 (0%) Bone marrow 6/466 (1%) Peripheral blood stem cell 29/1880 (2%) Cord blood 4/192 (2%) Donor type 1 Adult allo-hct recipients with AdV viremia ( 1000 copies/ml); n=39 Allo-HCT recipients with AdV viremia 1000 copies/ml n=39 n recipients with AdV viremia 1000 copies/ml/n with baseline characteristic (%) 1 Non-exclusive categories Conditioning T-cell depletion Matched-related 8/902 (1%) Matched-unrelated 19/976 (2%) Mismatched 10/326 (3%) Haploidentical 0/290 (0%) Myeloablative 21/1710 (1%) Non-myeloablative 18/828 (2%) Ex-vivo 9/737 (1%) Serotherapy (ATG) 8/728 (1%) Serotherapy (Campath) 16/228 (7%) None 6/845 (1%) 15
16 Age, donor type, and use of T-cell depletion were prognostic factors for AdV viremia 1000 copies/ml Adult and pediatric allo-hct recipients Stepwise reduction in risk with increasing age Age
17 Conclusions Pediatric Pediatric allo-hct recipients are screened routinely, with 1 in 3 (32%) having an identified AdV infection in the 6 months following their transplant 23% of recipients developed AdV viremia Just less than half of those with an AdV infection (14%) had AdV viremia 1000 copies/ml dsdna viral coinfection was common Adult Adult allo-hct recipients are less routinely screened 6% of recipients had an identified AdV infection in the 6 months following their transplant 3% developed AdV viremia 2% had AdV viremia 1000 copies/ml dsdna viral coinfection was common 17
18 Conclusions Pediatric and adult Adult Patient age was an independent predictor of AdV viremia 1000 copies/ml in the 6-months following allo-hct T-cell depletion and donor type are also independent risk factors These results suggest a need for re-examination of screening approaches, particularly for younger and at-risk adults 18
19 The AdVance centers FRANCE (10) Robert Debré Hospital, Paris CHU Angers Institut of Hematology, Lyon CHU Nancy CHU Montpellier CHU Bordeaux CHU Lyon CHU Nantes Saint Louis Hospital, Paris CHU Nice SPAIN (12) Hospital Universitario y Politécnico La Fe (2) Hospital Universitario 12 de Octubre Hospital Universitario La Paz Hospital Universitario de Salamanca Hospital Universitario Vall d'hebrón Hospital de la Santa Creu i Sant Pau (2) Hospital Universitario Reina Sofía Hospital Regional Universitario de Málaga Hospital Infantil Universitario Niño Jesús Hospital General Universitario Morales Meseguer ITALY (9) Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Centro Trapianti Midollo Osseo, Milano Hospital Casa Sollievo Sofferenza, San Giovanni Rotondo Azienda Ospedale Riuniti e Morelli Bianchi-Melacrino Centro Unico Regionale Trapianti Cellule Staminali e Terapia Cellulare, Reggio Calabria Pediatric Hematology/Oncology Department Policlinico San Matteo, Pavia GERMANY (7) Charité Campus Virchow Klinikum J. W. Goethe Universität Medizinische Hochschule Hannover Universitätsklinikum Jena Universitätsklinikum Köln Universitätsklinik Tübingen Klinikum der Universität München (LMU) UK (10) Royal Manchester Children's Hospital Bristol Royal Children s Hospital Sheffield Children's Hospital St. James's University Hospital and The General Infirmary, Leeds Great North Children's Hospital, Newcastle The NETHERLANDS (1) UMC Utrecht CZECH REPUBLIC (1) Hospital Motol, Praha 19 Great Ormond Street Hospital, London University College London Hospitals, University Hospital of Wales Cardiff The Royal Marsden Hospital, London Birmingham Children s Hospital Ospedale Civile Centro Trapianti Midollo Osseo Dip. Ematologia Medicina Trasfusionale e Biotecnologie, Pescara Pediatric Hematology/Oncology Department San Gerardo Hospital, Monza S.C. Oncoematologia Pediatrica e Centro Trapianti Regina Margherita, Torino Oncoematologia e TMO, Ospedale 'La Maddalena' Palermo Ospedale Bambin Gesù-Dip. Oncoematologia Pediatrica e Medicina Transfusionale, Roma
ADENOVIRUS VIRAL BURDEN IS ASSOCIATED WITH MORTALITY IN PEDIATRIC ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS: RESULTS FROM THE ADVANCE STUDY
ADENOVIRUS VIRAL BURDEN IS ASSOCIATED WITH MORTALITY IN PEDIATRIC ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS: RESULTS FROM THE ADVANCE STUDY Marco Zecca, 1 Kanchan Rao, 2 Antonio Pérez-Martínez,
More informationChimerix, Inc., Durham, NC; 5 Duke University Medical Center, Durham, NC
Improved Outcomes in Allogeneic Hematopoietic Cell Transplant Patients Treated with Brincidofovir (CMX001, BCV) for Disseminated Adenovirus Disease Compared to Literature: Updated Preliminary Results from
More informationIN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT PATIENTS WITH BRINCIDOFOVIR: FINAL 36 WEEK RESULTS FROM THE ADVISE TRIAL
TREATMENT OF ADENOVIRUS (AdV) INFECTION IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT PATIENTS WITH BRINCIDOFOVIR: FINAL 36 WEEK RESULTS FROM THE ADVISE TRIAL Vinod K. Prasad, MD, FRCP 1, Genovefa A. Papanicolaou,
More informationoptions in Myeloablative HSCT
Should Busilvex we use AlloSCT in AML options in Myeloablative HSCT Reduced Intensity or Myeloablative preparative protocols? Moderator: Andrea Bacigalupo Reduced Intensity: Arnon Nagler Myeloablative:
More informationMichael Grimley 1, Vinod Prasad 2, Joanne Kurtzberg 2, Roy Chemaly 3, Thomas Brundage 4, Chad Wilson 4, Herve Mommeja-Marin 4
Twice-weekly Brincidofovir (BCV, CMX1) Shows Promising Antiviral Activity in Immunocompromised Transplant Patients with Asymptomatic Adenovirus Viremia Michael Grimley 1, Vinod Prasad, Joanne Kurtzberg,
More informationIDWeek 2014, Session: 186, Late Breaker Oral Abstracts Saturday, October 11, 2014, Presentation No. LB 3
IDWeek 2014, Session: 186, Late Breaker Oral Abstracts Saturday, October 11, 2014, Presentation No. LB 3 Preliminary Safety Results and Antiviral Activity from the Open label Pilot Portion of a Phase 3
More informationDedicated to Preventing and Treating Life-Threatening Viral Infections. Randall Lanier Vice President, Biology
Dedicated to Preventing and Treating Life-Threatening Viral Infections Randall Lanier Vice President, Biology Adenovirus: Epidemiology and Treatment Options Allogeneic hematopoietic cell transplant (allo
More information4nd Patient and Family Day
4nd Patient and Family Day EBMT Slide template Barcelona 7 February 2008 EBMT 2010 Vienna, Austria ; www.ebmt.org History of Stem Cell Transplantation Appelbaum et al, NEJM 2006 What is EBMT? Scientific,
More informationClinical-Adult-Auto: X cellules souches hématopoïétiques adulte et. Clinical-Adult-Allo: X pédiatrique Cliniques ID:768
has completed following initial 1. Belgium Brussels Programme de transplantation de Cliniques Universitaires St Luc cellules souches hématopoïétiques adulte et ID:768 pédiatrique Cliniques Universitaires
More informationDEDICATED TO PREVENTING AND TREATING LIFE-THREATENING VIRAL INFECTIONS
DEDICATED TO PREVENTING AND TREATING LIFE-THREATENING VIRAL INFECTIONS February 22, 2016 Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements
More informationVirological Surveillance in Paediatric HSCT Recipients
Virological Surveillance in Paediatric HSCT Recipients Dr Pamela Lee Clinical Assistant Professor Department of Paediatrics & Adolescent Medicine Queen Mary Hospital LKS Faculty of Medicine, The University
More informationMUD SCT. Pimjai Niparuck Division of Hematology, Department of Medicine Ramathibodi Hospital, Mahidol University
MUD SCT Pimjai Niparuck Division of Hematology, Department of Medicine Ramathibodi Hospital, Mahidol University Outlines Optimal match criteria for unrelated adult donors Role of ATG in MUD-SCT Post-transplant
More informationBRINCIDOFOVIR WAS USED TO SUCCESSFULLY TREAT ADENOVIRUS INFECTIONS IN SOLID ORGAN TRANSPLANT RECIPIENTS AND OTHER IMMUNOCOMPROMISED PATIENTS
BRINCIDOFOVIR WAS USED TO SUCCESSFULLY TREAT ADENOVIRUS INFECTIONS IN SOLID ORGAN TRANSPLANT RECIPIENTS AND OTHER IMMUNOCOMPROMISED PATIENTS Diana F. Florescu, MD 1, Michael S. Grimley, MD 2, Genovefa
More informationUmbilical cord blood transplantation from unrelated donors in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
Stem Cell Transplantation SUPPLEMENTARY APPENDIX Umbilical cord blood transplantation from unrelated donors in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia José Luis Piñana,
More informationHC WAINWRIGHT 20 TH ANNUAL GLOBAL INVESTMENT CONFERENCE GARRETT NICHOLS, MD, MS CHIEF MEDICAL OFFICER SEPTEMBER 6, 2018
HC WAINWRIGHT 20 TH ANNUAL GLOBAL INVESTMENT CONFERENCE GARRETT NICHOLS, MD, MS CHIEF MEDICAL OFFICER SEPTEMBER 6, 2018 Forward-Looking Statements These slides and the accompanying oral presentation contain
More informationSIOPEL 6. International Childhood Liver Tumour Strategy Group - SIOPEL. Eudract Number:
SIOPEL 6 A multi-centre open label randomised phase III trial of the efficacy of Sodium Thiosulphate in reducing ototoxicity in patients receiving cisplatin chemotherapy for STANDARD RISK HEPATOBLASTOMA
More informationMulti-Virus-Specific T cell Therapy for Patients after HSC and CB Transplant
Multi-Virus-Specific T cell Therapy for Patients after HSC and CB Transplant Hanley PJ, Krance BR, Brenner MK, Leen AM, Rooney CM, Heslop HE, Shpall EJ, Bollard CM Hematopoietic Stem Cell Transplantation
More informationMantle cell lymphoma Allo stem cell transplantation in relapsed and refractory patients
Mantle cell lymphoma Allo stem cell transplantation in relapsed and refractory patients Olivier Hermine MD, PhD Department of Hematology INSERM and CNRS, Imagine Institute Necker Hospital Paris, France
More informationDonatore HLA identico di anni o MUD giovane?
Donatore HLA identico di 60-70 anni o MUD giovane? Stella Santarone Dipartimento di Ematologia, Medicina Trasfusionale e Biotecnologie Pescara AGENDA 1. Stem Cell Donation: fatalities and severe events
More informationPreventative/Preemptive Adoptive Transfer of Peptide Stimulated CMV/EBV Specific T-cells in Patients After Allogeneic Stem Cell Transplantation
Find Studies About Studies Submit Studies Resources About Site Preventative/Preemptive Adoptive Transfer of Peptide Stimulated CMV/EBV Specific T-cells in Patients After Allogeneic Stem Cell Transplantation
More informationMedical University of Vienna Reaccreditation 1 ID:700. Initial accreditation ID:777. Cliniques Universitaires St Luc Reaccreditation 2 ID:768
1. Austria Vienna BMT Unit, First Medical Department 2. Belgium Centrum voor Oncologie, Autoloog stamceltransplantatie programma Medical University of Vienna AZ Turnnhout vzw, Campus Sint- Elisabeth ID:700
More informationBendamustine + Rituximab (BR) Project
Bendamustine + Rituximab (BR) Project Efficacy and tolerability of Bendamustine and Rituximab in first line and second line treatment in CLL An observational study proposed by the ERIC-GIMEMA groups Rationale
More information2016 BMT Tandem Meetings
ASBMT CIBMTR 2016 BMT Tandem Meetings for Prevention of Cytomegalovirus after Allogeneic Hematopoietic Cell Transplantation in CMV-Seropositive Patients A Randomized, Double-Blind, -Controlled, Parallel-Group
More informationEmerging CMV Resistance Profile for CMX001
Emerging CMV Resistance Profile for CMX001 International Conference on Antiviral Research May 15, 2013 Randall Lanier, PhD Forward Looking Statements These slides and the accompanying oral presentation
More informationJP MORGAN HEALTHCARE CONFERENCE M. MICHELLE BERREY, MD, MPH CHIEF EXECUTIVE OFFICER JANUARY 10, 2019
JP MORGAN HEALTHCARE CONFERENCE M. MICHELLE BERREY, MD, MPH CHIEF EXECUTIVE OFFICER JANUARY 10, 2019 Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking
More informationFederica Galaverna, 1 Daria Pagliara, 1 Deepa Manwani, 2 Rajni Agarwal-Hashmi, 3 Melissa Aldinger, 4 Franco Locatelli 1
Administration of Rivogenlecleucel (Rivo-cel, BPX-501) Following αβ T- and B-Cell Depleted Haplo-HSCT in Children With Transfusion-Dependent Thalassemia Federica Galaverna, 1 Daria Pagliara, 1 Deepa Manwani,
More informationSwitch from Existing Antivirals to Brincidofovir Leads to Improving Renal Function
Switch from Existing Antivirals to Brincidofovir Leads to Improving Renal Function Marion Morrison MD 1, Robin Avery MD 2, Eun Kwak MD 3, Tom Brundage MS 1, Herve Mommeja-Marin MD 1 2014 World Transplant
More informationSupplementary Online Content
Supplementary Online Content Ageno W, Riva N, Schulman S, et al. Long-term clinical outcomes of splanchnic vein thrombosis: results of an international registry. JAMA Intern Med. Published online July
More informationEBMT Society EBMT. History Organisation Studies Activity Philosophy. EBMT Website. European Group for Blood and Marrow Transplantation
EBMT EBMT Organisation and Activities J Apperley 13th. ESH-EBMT Training Course Targu Mures May 24 26, 2010 History Organisation Studies Activity Philosophy EBMT Website www.ebmt.org EBMT Society European
More informationDisclosure. Objectives 1/22/2015
Evaluation of the Impact of Anti Thymocyte Globulin (ATG) on Post Hematopoietic Stem Cell Transplant (HCT) Outcomes in Patients Undergoing Allogeneic HCT Katie S. Kaminski, PharmD, CPP University of North
More informationHaploidentical Transplantation: The Answer to our Donor Problems? Mary M. Horowitz, MD, MS CIBMTR, Medical College of Wisconsin January 2017
Haploidentical Transplantation: The Answer to our Donor Problems? Mary M. Horowitz, MD, MS CIBMTR, Medical College of Wisconsin January 2017 Allogeneic Transplant Recipients in the US, by Donor Type 9000
More informationThe National Marrow Donor Program. Graft Sources for Hematopoietic Cell Transplantation. Simon Bostic, URD Transplant Recipient
1988 199 1992 1994 1996 1998 2 22 24 26 28 21 212 214 216 218 Adult Donors Cord Blood Units The National Donor Program Graft Sources for Hematopoietic Cell Transplantation Dennis L. Confer, MD Chief Medical
More informationDisclosures. Investigator-initiated study funded by Astellas
Disclosures Investigator-initiated study funded by Astellas 1 Background Widespread use of preemptive therapy strategies has decreased CMV end-organ disease to 5-8% after HCT. Implications for development
More informationDr. Joseph McGuirk Professor of Medicine, BMT Medical Director, Interim Director, Division of Hematology/Oncology
Advances in Autologous and Allogeneic Stem Cell Transplantation Dr. Joseph McGuirk Professor of Medicine, BMT Medical Director, Interim Director, Division of Hematology/Oncology April 12, 2014 Disclosures
More informationAllogeneic bone marrow transplantation from
Transplantation & Cell Therapy Unrelated donor marrow transplantation: an update of the experience of the Italian Bone Marrow Transplant Group (GITMO) decision making and problem solving haematologica
More informationShort Study Report for Health Authorities
the Active Title of the Study Randomised trial of single agent doxorubicin versus doxorubicin plus ifosfamide in the first line treatment of advanced or metastatic soft tissue sarcoma Investigators & Study
More informationTrends in Hematopoietic Cell Transplantation. AAMAC Patient Education Day Oct 2014
Trends in Hematopoietic Cell Transplantation AAMAC Patient Education Day Oct 2014 Objectives Review the principles behind allogeneic stem cell transplantation Outline the process of transplant, some of
More informationDisclosures of: Emanuele Angelucci
Company name Novartis Disclosures of: Emanuele Angelucci Research support Employee Consultant Stockholder Speakers bureau Advisory board Chair of TELESTO pro Other EBMT 2012 Educational Session Haemoglobinopathy
More informationLate complications after hematopoietic stem cell transplant in adult patients
Late complications after hematopoietic stem cell transplant in adult patients Gérard Socié, MD, PhD Hematology/Transplantation, Hospital Saint Louis, Paris, France Synopsis H S C T Allogeneic HSCT activity
More informationSamples Available for Recipient Only. Samples Available for Recipient and Donor
Unrelated HCT Research Sample Inventory - Summary for First Allogeneic Transplants in CRF and TED with biospecimens available through the CIBMTR Repository stratified by availability of paired samples,
More informationPractical experience in implementing surveillance of antiviral resistance in several European countries in accordance with personal data regulation
Practical experience in implementing surveillance of antiviral resistance in several European countries in accordance with personal data regulation Katja Deterding Medizinische Hochschule Hannover Antiviral
More information1Q2018 EARNINGS CALL MAY 7, 2018
1Q2018 EARNINGS CALL MAY 7, 2018 Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements and information within the meaning of the Private Securities
More informationEarly interim PET (PET2) in Hodgkin Lymphoma patients treated with ABVD. An International Validation Study (IVS).
Early interim PET (PET2) in Hodgkin Lymphoma patients treated with ABVD. An International Validation Study (IVS). A Gallamini Hematology Department and BMT Unit, Santa Croce Hospital Cuneo - Italy S. Barrington
More informationCover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/1887/20898 holds various files of this Leiden University dissertation. Author: Jöris, Monique Maria Title: Challenges in unrelated hematopoietic stem cell transplantation.
More informationSamples Available for Recipient and Donor
Unrelated HCT Research Sample Inventory - Summary for First Allogeneic Transplants in CRF and TED with biospecimens available through the CIBMTR Repository stratified by availability of paired samples,
More informationSamples Available for Recipient Only. Samples Available for Recipient and Donor
Unrelated HCT Research Sample Inventory - Summary for First Allogeneic Transplants in CRF and TED with biospecimens available through the CIBMTR Repository stratified by availability of paired samples,
More informationImproving the Outcome of Stem Cell Transplants for Cancer Treatment Using Multivirus-Specific T Cells (Viralym-M)
OFF-THE-SHELF T CELL THERAPY FOR CANCER PATIENTS FOLLOWING STEM CELL TRANSPLANT Improving the Outcome of Stem Cell Transplants for Cancer Treatment Using Multivirus-Specific T Cells (Viralym-M) Ann M.
More informationRevista Cubana de Hematología, Inmunología y Hemoterapia. 2017; 36 (Suplemento).
Depletion of TCR alpha/beta+ T-lymphocytes from grafts for haplo haematopoietic CELL transplantation (HCT) in children Heilmann C, Ifversen M, Haastrup E, Fischer-Nielsen A. Haematopoietic Cell Transplantation
More informationReduced-intensity Conditioning Transplantation
Reduced-intensity Conditioning Transplantation Current Role and Future Prospect He Huang M.D., Ph.D. Bone Marrow Transplantation Center The First Affiliated Hospital Zhejiang University School of Medicine,
More informationHematopoietic Stem Cell Transplant in Sickle Cell Disease- An update
Hematopoietic Stem Cell Transplant in Sickle Cell Disease- An update Dr Chirag A Shah Diplomate American Board of Hematology and Medical Oncology Director, Dept of Hemato-Oncology and Stem Cell Transplant
More informationLa Terapia Cellulare nella PML
Update sulle Malattie Infiammatorie e Infettive del SNC Pavia, 25 maggio 218 La Terapia Cellulare nella PML Sabrina Basso Oncoematologia Pediatrica Fondazione IRCCS Policlinico S. Matteo, Pavia Polyomavirus
More informationAlloreattività e Tolleranza nei Trapianti di Cellule Staminali Emopoietiche Allogeniche
Alloreattività e Tolleranza nei Trapianti di Cellule Staminali Emopoietiche Allogeniche Massimo Fabrizio Martelli Ematologia ed Immunologia Clinica Università degli Studi di Perugia 41 Congresso Nazionale
More informationHaploidentical Transplantation today: and the alternatives
Haploidentical Transplantation today: and the alternatives Daniel Weisdorf MD University of Minnesota February, 2013 No matched sib: where to look? URD donor requires close HLA matching and 3-12 weeks
More informationRob Wynn RMCH & University of Manchester, UK. HCT in Children
Rob Wynn RMCH & University of Manchester, UK HCT in Children Summary Indications for HCT in children Donor selection for Paediatric HCT Using cords Achieving engraftment in HCT Conditioning Immune action
More informationIl Trapianto da donatore MUD. Alessandro Rambaldi
Il Trapianto da donatore MUD Alessandro Rambaldi Overview Comparison of outcomes of allo- HSCT from matched related and unrelated donors. We need evidence based results! Is the Dme needed to find an unrelated
More informationManagement of Viral Infections in HCT
Management of Viral Infections in HCT Alison Coats, APRN-BC Liza Rodriguez, APRN, AOCNP Objectives Recognize viral infections that affect patients after hematopoietic cell transplant (HCT) Describe the
More informationRegular Article. Adoptive T-cell therapy with hexon-specific Th1 cells as a treatment of refractory adenovirus infection after HSCT TRANSPLANTATION
Regular Article From www.bloodjournal.org by guest on January 21, 2019. For personal use only. TRANSPLANTATION Adoptive T-cell therapy with hexon-specific Th1 cells as a treatment of refractory adenovirus
More informationLaboratorio di Terapia Cellulare Stefano Verri, Ospedale San Gerardo, Monza, Italy 5
Stem Cells International Volume 22, Article ID 69236, 6 pages doi:.55/22/69236 Clinical Study Mesenchymal Stromal Cells Do Not Increase the Risk of Viral Reactivation Nor the Severity of Viral Events in
More informationLe infezioni fungine nel trapianto di cellule staminali emopoietiche. Claudio Viscoli Professor of Infectious Disease University of Genova, Italy
Le infezioni fungine nel trapianto di cellule staminali emopoietiche Claudio Viscoli Professor of Infectious Disease University of Genova, Italy Potential conflicts of interest Received grants as speaker/moderator
More informationEBMT Complications and Quality of Life Working Party Educational Course
EBMT Complications and Quality of Life Working Party Educational Course Organisers: R. Duarte, G. Basak 23-24 October 2014, Warsaw, Poland #EBMT2014 www.ebmt.org EBMT Complications and Quality of Life
More informationThe Role of Outcomes Registries in Blood and Marrow Transplantation Mary M Horowitz, MD, MS Cape Town, South Africa November 2014
The Role of Outcomes Registries in Blood and Marrow Transplantation Mary M Horowitz, MD, MS Cape Town, South Africa November 2014 Worldwide Network for Blood and Marrow Transplantation Transplants A Little
More informationRapid and Robust CD4+ and CD8+ T-, NK-, BTitel and Monocyte Cell Reconstitution after Nicotinamide-Expanded Cord Blood (NiCord) Transplantation
Rapid and Robust CD4+ and CD8+ T-, NK-, BTitel and Monocyte Cell Reconstitution after Nicotinamide-Expanded Cord Blood (NiCord) Subtitel Transplantation Boelens/Nierkens lab Jaap Jan Boelens, Central Immune
More informationAllogeneic Hematopoietic Stem Cell Transplantation: State of the Art in 2018 RICHARD W. CHILDS M.D. BETHESDA MD
Allogeneic Hematopoietic Stem Cell Transplantation: State of the Art in 2018 RICHARD W. CHILDS M.D. BETHESDA MD Overview: Update on allogeneic transplantation for malignant and nonmalignant diseases: state
More informationValidation of the acute leukemia-ebmt score for prediction of mortality following allogeneic stem cell transplantation in a multi-center GITMO cohort
Received: 16 December 2016 Revised: 22 January 2017 Accepted: 3 February 2017 DOI: 10.1002/ajh.24677 RESEARCH ARTICLE Validation of the acute leukemia-ebmt score for prediction of mortality following allogeneic
More informationEuropean Expert Paediatric Oncology Reference Network for Diagnostics and Treatment ExPO-r-Net
Consumers, Health and Food Executive Agency European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment 2013 12 07 ExPO-r-Net 1 Quality of the partnership Background The project
More informationOne Day BMT Course by Thai Society of Hematology. Management of Graft Failure and Relapsed Diseases
One Day BMT Course by Thai Society of Hematology Management of Graft Failure and Relapsed Diseases Piya Rujkijyanont, MD Division of Hematology-Oncology Department of Pediatrics Phramongkutklao Hospital
More informationDedicated to Preventing and Treating Life-Threatening Viral Infections. W. Garrett Nichols, MD, MS Chief Medical Officer
Dedicated to Preventing and Treating Life-Threatening Viral Infections W. Garrett Nichols, MD, MS Chief Medical Officer Chimerix: Dedicated to Discovering, Developing and Commercializing Antivirals to
More informationTrial record 1 of 1 for:
This site became the new ClinicalTrials.gov on June 19th. Learn more. We will be updating this site in phases. This allows us to move faster and to deliver better services. Show less IMPORTANT: Listing
More informationChildhood Acute Lymphoblastic Leukemia
Childhood Acute Lymphoblastic Leukemia Ajay Vora Editor Childhood Acute Lymphoblastic Leukemia Editor Ajay Vora Department of Paediatric Haemotology Sheffield Children's Hospital NHS Trust University of
More informationMINUTES AND OVERVIEW PLAN CIBMTR WORKING COMMITTEE FOR INFECTION AND IMMUNE RECONSTITUTION San Diego, CA Thursday, February 12, 2015, 12:15 2:15 pm
MINUTES AND OVERVIEW PLAN CIBMTR WORKING COMMITTEE FOR INFECTION AND IMMUNE RECONSTITUTION San Diego, CA Thursday, February 12, 2015, 12:15 2:15 pm Co-Chair: Michael Boeckh, MD, Fred Hutchinson Cancer
More informationSustained HIV- 1 remission following homozygous CCR5 delta- 32 allogeneic haemopoetic stem cell transplantion
Sustained HIV- 1 remission following homozygous CCR5 delta- 32 allogeneic haemopoetic stem cell transplantion R Gupta 1, A Abdulijawad 2, L McCoy 2, D Peppa 3, M Salgado 4, J Martinez- Picado 4, A Wensing
More informationCOHEM Barcellona 2012 Hemoglobinopathies debate
COHEM Barcellona 2012 Hemoglobinopathies debate September 8, 2012: h. 10:30-12:00 Hall: A Is it justified to perform BMT in hemoglobinopathies using unrelated and/or partially mismatched donors? HSCT indication
More informationYes Antonio M. Risitano, M.D., Ph.D. Head of Bone Marrow Transplantation Unit Federico II University of Naples
4ème Journée Nationale Maladies Rares Immuno-Hématologiques Paris, June 7th 2018 Matched unrelated upfront transplantation in idiopathic aplastic anemia? Yes Antonio M. Risitano, M.D., Ph.D. Head of Bone
More informationunder the aegis of cover picture: Chiostro d Onore University of Milan
under the aegis of cover picture: Chiostro d Onore University of Milan Milan. 2,3 July 2012 Palazzo Visconti MEETING AIM In the last year the therapeutic scenario of chronic hepatitis C has been subverted
More informationHaplo vs Cord vs URD Debate
3rd Annual ASBMT Regional Conference for NPs, PAs and Fellows Haplo vs Cord vs URD Debate Claudio G. Brunstein Associate Professor University of Minnesota Medical School Take home message Finding a donor
More informationThe question is not whether or not to deplete T-cells, but how to deplete which T-cells
The question is not whether or not to deplete T-cells, but how to deplete which T-cells CD34+ positive selection Negative Depletion of: CD3/CD19 TcRαβ/CD19 T-cell depletion: positive selection versus negative
More informationBroad spectrum antiviral T cells for viral complications after hematopoietic stem cell transplantation
Editorial Page 1 of 5 Broad spectrum antiviral T cells for viral complications after hematopoietic stem cell transplantation Britta Maecker-Kolhoff 1,2, Britta Eiz-Vesper 2,3 1 Department of Pediatric
More informationRiposta immune versus stato immune
Riposta immune versus stato immune Russell E. Lewis U.O. Malattie Infettive, Policlinico S. Orsola-Malpighi Dipartimento di Scienze Mediche e Chirurgiche Alma Mater Studiorum Università di Bologna Immunodeficiency
More informationThe number of patients registered on the kidney transplant list this year fell by 4% from 5,233 to 5,033
5 Kidney Activity Kidney Activity Key messages The number of patients registered on the kidney transplant list this year fell by 4% from 5,233 to 5,033 The number of deceased kidney donors increased by
More informationDisclosure for Ralf Trappe, MD
Disclosure for Ralf Trappe, MD In compliance with ACCME policy, ASH requires the following disclosures to the session audience: Research Support/P.I. Employee Consultant Major Stockholder Speakers Bureau
More informationIntroduction to Clinical Hematopoietic Cell Transplantation (HCT) George Chen, MD Thursday, May 03, 2018
Introduction to Clinical Hematopoietic Cell Transplantation (HCT) George Chen, MD Thursday, May 03, 2018 The transfer of hematopoietic progenitor and stem cells for therapeutic purposes Hematopoietic Cell
More informationPhase II Study of Subcutaneous Injection Depot of Octreotide in Patients With Acromegaly and Ne uroe ndocrine Tumours (NETs)
A service of the U.S. National Institutes of Health Trial record 1 of 4 for: CAMURUS Previous Study Return to List Next Study Phase II Study of Subcutaneous Injection Depot of Octreotide in Patients With
More informationCopyright information:
Risk Factors and Utility of a Risk-Based Algorithm for Monitoring Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections in Pediatric Recipients after Allogeneic Hematopoietic Cell Transplantation
More informationHaploidentical Stem Cell Transplantation with post transplantation Cyclophosphamide for the treatment of Fanconi Anemia
Haploidentical Stem Cell Transplantation with post transplantation Cyclophosphamide for the treatment of Fanconi Anemia Carmem Bonfim Director Pediatric Blood and Marrow Transplantation Program HC Federal
More informationEvidence from bone marrow transplantation
Evidence from bone marrow transplantation Gianluigi Mancardi Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, Ospedale Policlinico San Martino, University
More informationTable Of Content. Outputs... 8
Table Of Content Developing a training and resource package for improving the sexual and reproductive health of people living with HIV/AIDS... 3 Summary... 4 Coordinator, Leader contact and partners...
More informationDECOY CELLS IN KIDNEY TRANSPLANT RECIPIENTS
DECOY CELLS IN KIDNEY TRANSPLANT RECIPIENTS GIOVANNI BATTISTA FOGAZZI CLINICAL AND RESEARCH LABORATORY ON URINARY SEDIMENT U.O. DI NEFROLOGIA E DIALISI FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO
More informationClinical Aspect and Application of Laboratory Test in Herpes Virus Infection. Masoud Mardani M.D,FIDSA
Clinical Aspect and Application of Laboratory Test in Herpes Virus Infection Masoud Mardani M.D,FIDSA Shahidhid Bh BeheshtiMdi Medical lui Universityit Cytomegalovirus (CMV), Epstein Barr Virus(EBV), Herpes
More informationAbout OMICS Group Conferences
About OMICS Group OMICS Group International is an amalgamation of Open Access publications and worldwide international science conferences and events. Established in the year 2007 with the sole aim of
More informationStem Cell Transplantation
Stem Cell Transplantation Evelyne Willems Centre Hospitalier Universitaire, ULg, Liège Post-ASH meeting, January 11, 2012, Brussels Plan 1. Select the patient: validation of HCT-CI 2. Select the donor
More informationAML:Transplant or ChemoTherapy?
AML:Transplant or ChemoTherapy? 1960 s: Importance of HLA type in Animal Models Survival of Dogs Given 1000 RAD TBI and a Marrow Infusion from a Littermate Matched or Mismatched for Dog Leucocyte Antigens
More informationUnrelated allogeneic transplantation for severe aplastic anemia is a treatment
ARTICLE Stem Cell Transplantation EUROPEAN HEMATOLOGY ASSOCIATION Ferrata Storti Foundation Unrelated alternative donor transplantation for severe acquired aplastic anemia: a study from the French Society
More informationImpatto clinico nel trapianto allogenico da donatori non familiari dei mismatch al locus HLA-DPB1
Impatto clinico nel trapianto allogenico da donatori non familiari dei mismatch al locus HLA-DPB1 Gruppo Italiano Trapianto Midollo Osseo Italian Bone Marrow Donor Registry Immunogenetics and HSCT Units
More informationInfective hepatic complications in HSCT patients. Simone Cesaro. Pediatric Hematology Oncology Verona, Italy. Session II: organ specific complications
Session II: organ specific complications Infective hepatic complications in HSCT patients Simone Cesaro Pediatric Hematology Oncology Verona, Italy simone.cesaro@ospedaleuniverona.it Liver complications
More informationSupervivencia a 5 años de Pacientes Coinfectados por VHC-VIH Trasplantados Hepáticos: un Estudio de Casos y Controles
I Congreso de GESIDA Madrid, 21-24 de Octubre del 2009. Supervivencia a 5 años de Pacientes Coinfectados por VHC-VIH Trasplantados Hepáticos: un Estudio de Casos y Controles José M. Miró, 1 Miguel Montejo,
More informationA comparison between allogeneic stem cell transplantation from unmanipulated haploidentical and unrelated donors in acute leukemia
Piemontese et al. Journal of Hematology & Oncology (2017) 10:24 DOI 10.1186/s13045-017-0394-2 RESEARCH A comparison between allogeneic stem cell transplantation from unmanipulated haploidentical and unrelated
More informationEuropean Risk Management Plan. Measures impairment. Retreatment after Discontinuation
European Risk Management Plan Table 6.1.4-1: Safety Concern 55024.1 Summary of Risk Minimization Measures Routine Risk Minimization Measures Additional Risk Minimization Measures impairment. Retreatment
More informationCell-based immunotherapy products for the treatment of blood cancers and inherited blood disorders. Company Presentation June 2016
Cell-based immunotherapy products for the treatment of blood cancers and inherited blood disorders Company Presentation June 2016 Disclaimer These slides and the accompanying oral presentation contain
More informationThe number of patients registered on the kidney transplant list this year fell by 7% from 5686 to 5275
5 Kidney Activity Kidney Activity Key messages The number of patients registered on the kidney transplant list this year fell by 7% from 5686 to 5275 The number of deceased kidney donors increased by 7%
More informationDiagnosingneurotropicvirus infectionsin immunocompromised individuals
Molecular Virology Unit, Microbiology and Virology Dept IRCCS Policlinico San Matteo, Pavia DptClinical and Surgical Sciences, Diagnostics and Pediatrics University of Pavia Diagnosingneurotropicvirus
More information